There’s a curious, market-wide rout in play right now off the back of Chinese AI startup DeepSeek. The risk of a far cheaper solution is rattling US futures and taking a toll in Europe, too. At our early copy time of just before midday, the AIM All Share index is down four and a half points at 710.49.
- Good Energy +22%
- Beacon Energy +17%
- Abingdon Health +10%
- Woodbois -24%
- GENinCode -14%
Good Energy LON:GOOD was topping the board mid-session, trading up some 22% following news that takeover terms had been agreed with Esyasoft Investment Holdings. An offer of 490p has been made and that’s close to fully priced in – a 66% uplift from the pre-offer price.
- Small Cap Stocks: Good Energy, Distil, Corcel
- Three Quick Facts: Trainline, Computacenter, Good Energy
Beacon Energy [LON:BCE] was in second place, up 17%. The company announced that it had become a cash shell under AIM rules a couple of weeks back and needs to resolve this to avoid delisting. Whether the move hints at hopes of a resolution here remains to be seen but the stock is trading on a massive spread and volumes remain very low.
- Small Cap Stocks: Oracle Power, Surface Transforms, Goldstone Resources
- Small Cap Stocks: RBG, Hummingbird, Loungers
Abingdon Health LON:ABDX gets the notable mention, up 10%. That was driven by news that the company had received funding of £800k by a number of leading institutions to help eradicate malaria. The initiative is to further development and manufacture of a new rapid diagnostic test for Plasmodium vivax malaria.
- Small Cap Stocks: Hummingbird, LPA Group, Cadence Minerals
- Three Quick Facts: Computacenter, Prudential, Abingdon Health
Woodbois LON:WBI was the biggest faller mid-session, down 24%. There’s no official news out but volumes are notably elevated and this extends the run lower we’ve seen in play since the start of the year – itself part of a bigger down trend. Is news incoming?
GENinCode LON:GENI was 14% lower, with shares continuing to give back last week’s gains. On Thursday it was announced that the company’s products were included in the US clinical lab fee schedule, paving the way for wider adoption, but the stock has now given back as much as 80% of that rally.